Ravicti Drug Interactions
Currently displaying 249 drugs known to have a moderate interaction with Ravicti (glycerol phenylbutyrate).
Moderate interactions with Ravicti (glycerol phenylbutyrate)
Note: Showing generic names only.
A
- abemaciclib
- acalabrutinib
- acebutolol
- acetaminophen
- alfentanil
- alpelisib
- alprazolam
- amitriptyline
- amoxapine
- amphetamine
- aripiprazole
- armodafinil
- asenapine
- atomoxetine
- avacopan
- avapritinib
B
- belinostat
- belumosudil
- benzphetamine
- betamethasone
- betaxolol ophthalmic
- bortezomib
- brexpiprazole
- bromocriptine
- budesonide
- buspirone
C
- cabozantinib
- capivasertib
- capmatinib
- carbamazepine
- cariprazine
- carvedilol
- cevimeline
- chlorpheniramine
- chlorpromazine
- cinacalcet
- cisapride
- citalopram
- clomipramine
- clozapine
- codeine
- cortisone
- crizotinib
- cyclobenzaprine
- cyclosporine
D
- daridorexant
- darifenacin
- darolutamide
- dasatinib
- deflazacort
- delavirdine
- desipramine
- deutetrabenazine
- dexamethasone
- dexfenfluramine
- dextroamphetamine
- dextromethorphan
- dihydroergotamine
- diphenhydramine
- dolasetron
- doravirine
- doxepin
- dronedarone
- drospirenone
- duloxetine
E
- elacestrant
- elagolix
- eliglustat
- entrectinib
- enzalutamide
- ergonovine
- ergotamine
- erlotinib
- escitalopram
- estradiol
- ethinyl estradiol
- etonogestrel
- everolimus
F
- fenfluramine
- fentanyl
- fesoterodine
- finerenone
- flecainide
- fludrocortisone
- fluoxetine
- fluphenazine
- fluvoxamine
- fostamatinib
G
H
I
L
- labetalol
- lapatinib
- larotrectinib
- lefamulin
- lemborexant
- lenacapavir
- leniolisib
- levobetaxolol ophthalmic
- levobunolol ophthalmic
- levonorgestrel
- lithium
- lonafarnib
- loratadine
M
- macimorelin
- macitentan
- maprotiline
- maribavir
- mavacamten
- meclizine
- medroxyprogesterone
- mefloquine
- mesoridazine
- methadone
- methamphetamine
- methdilazine
- methotrimeprazine
- methylergonovine
- methylprednisolone
- methysergide maleate
- metoclopramide
- metoprolol
- mexiletine
- midazolam
- midodrine
- mirabegron
- mirtazapine
- mobocertinib
- modafinil
N
O
- olanzapine
- oliceridine
- olutasidenib
- omaveloxolone
- ondansetron
- orlistat
- osilodrostat
- oxamniquine
- oxycodone
P
- pacritinib
- paliperidone
- palovarotene
- pancreatin
- pancrelipase
- panobinostat
- pantoprazole
- paroxetine
- pemigatinib
- penbutolol
- perampanel
- perphenazine
- phenobarbital
- pimavanserin
- pimozide
- pindolol
- pirfenidone
- pirtobrutinib
- pitolisant
- ponatinib
- praziquantel
- prednisolone
- prednisone
- primidone
- prochlorperazine
- promazine
- promethazine
- propafenone
- propiomazine
- propoxyphene
- propranolol
- protriptyline
Q
R
S
- selegiline
- selpercatinib
- selumetinib
- sertraline
- silodosin
- sirolimus
- sirolimus protein-bound
- sorafenib
- sotorasib
- sparsentan
- stiripentol
- sufentanil
- sunitinib
T
- tacrolimus
- tadalafil
- tamoxifen
- tamsulosin
- tazemetostat
- temsirolimus
- tepotinib
- tetrabenazine
- thiethylperazine
- timolol
- timolol ophthalmic
- tolterodine
- topiramate
- tramadol
- trazodone
- triamcinolone
- trifluoperazine
- triflupromazine
- trimeprazine
- trimipramine
- tucatinib
U
V
- valbenazine
- vamorolone
- venlafaxine
- vinblastine
- vincristine
- vinorelbine
- vonoprazan
- vorinostat
- vortioxetine
Z
Ravicti disease interactions
There are 4 disease interactions with Ravicti (glycerol phenylbutyrate) which include:
More about Ravicti (glycerol phenylbutyrate)
- Ravicti consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: urea cycle disorder agents
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.